Orofresh OS5%+1%
Oral Solution
Rhubarb Extract + Salicylic Acid
Ziska Pharmaceuticals Ltd.
Product Code : 12762
10% Off
Best PriceTk
/
1
Medicine overview
Indications of Orofresh OS 5%+1%
This oral solution is indicated in the treatment of acute and chronic inflammations of the mucosas of the mouth, gums and throat (Aphthous Ulcer, Cold Sore, Gingivitis, Periodontitis, Dental Hypersensitivity, Dental Plaque, Denture Irritation).
Composition
Each 1 ml oral solution contains Rhubarb extract BP 0.05 gm (equivalent to anthraquinone glycosides 0.005 gm) and Salicylic acid BP 0.01 gm.
Theropeutic Class
Oral preparations
Pharmacology
This oral solution exerts an anti-inflammatory action in the cases of inflammatory infections on the mucosa of the mouth or throat. Its analgesic properties allow to rapidly suppressing pains and the sensitivity of the tissue submitted to inflammatory processes. This oral solution allows that, after a short time, mucosa resume their normal physiological functions, without exerting any harmful action on the tissues. It's use is easy and painless. It is well tolerated by individuals sensitive to iodine.
Dosage & Administration of Orofresh OS 5%+1%
Adults (including the elderly): To be applied to the inflamed oral mucosa (after removing any dentures) three or four times daily using the brush provided. Avoid rinsing the mouth or eating for 15 minutes after application. Always keep the cap closed immediately after every use.Children: Not recommended below the age of 12 years
Dosage of Orofresh OS 5%+1%
Adults: To be applied to the inflamed oral mucosa (after removing any dentures) 3 to 4 times daily using the brush provided. Avoid rinsing the mouth or eating for 15 minutes after application. Always keep the cap closed immediately after every use.Children: As per consultation with a registered physician, it is recommended below the age of 12 years.
Interaction of Orofresh OS 5%+1%
There are no known interactions with the preparation documented.
Contraindications
Hypersensitivity to any of the constituents.
Side Effects of Orofresh OS 5%+1%
A transient local burning sensation at the site of application occurs very commonly. Temporary discoloration of teeth or oral mucosa has been described commonly following administration of the oral solution.
Pregnancy & Lactation
Pregnancy: Animal studies are insufficient with respect to effects on pregnancy and/or embryonal / foetal development. The potential risk for human is unknown. Caution should be exercised when prescribing to pregnant women.Lactation: Anthranoid glycosides derived from rhubarb may be excreted in breast milk. However, at therapeutic doses of oral solution, it is not known whether these, or salicylic acid are excreted in breast milk. A decision on whether to continue breast feeding or to continue therapy with oral solution should be made taking into account the benefit of breast-feeding to the child and benefit of oral solution therapy to the women.
Precautions & Warnings
Each bottle of the oral solution should be used by only one person.
Overdose Effects of Orofresh OS 5%+1%
Overdose associated with a local application is unlikely, although the extent of systemic absorption of salicylic acid and anthraquinone derivatives is not known. Systemic overdose following ingestion might lead to abdominal cramping, diarrhea, and possibly salicylism (presenting as hyperventilation, tinnitus, deafness, vasodilation, sweating).
Storage Conditions
Store in a cool and dry place, protected from light.
Drug Classes
Oral preparations
Mode Of Action
Salicylic acid works by blocking the action of a substance in the body called cyclo-oxygenase. This extract contains anthraquinone glycosides, which relieve inflammation. This is well absorb into the oral mucosa.
Pregnancy
Pregnancy: Animal studies are insufficient with respect to effects on pregnancy and-or embryonal/foetal development. The potential risk for humans is unknown. Caution should be exercised when prescribing to pregnant women.Lactation: Anthraquinone glycosides derived from rhubarb may be excreted in breast milk. However, at therapeutic doses of oral solution, it is not known whether these or salicylic acid are excreted in breast milk. A decision on whether to continue breast feeding or to continue therapy with an oral solution should be made taking into account the benefit of breast-feeding to the child and benefit of oral solution therapy to the woman.
Disclaimer
The information provided is accurate to our best practices, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy. The absence of specific information about a drug should not be seen as an endorsement. We are not responsible for any consequences resulting from this information, so consult a healthcare professional for any concerns or questions.